ALLK News and Press, Allakos Inc. From 03/18/20

SAN FRANCISCO, March 18, 2020 (GLOBE NEWSWIRE) -- Hagens Berman urges Allakos Inc. ( NASDAQ: ALLK ) investors who have suffered significant losses to submit their losses now .  A securities fraud class action has been filed against the Company and certain investors may have valuable...

New York, New York--(Newsfile Corp. - March 16, 2020) -  Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Allakos Inc. (NASDAQ: ALLK) ("Allakos" or the "Company") of the May 11, 2020 deadline to seek the role of lead plaintiff in a federal securities ...

Allakos (NASDAQ: ALLK ) initiated with Underperform rating and $34 (42% downside risk) price target at SMBC Nikko. More news on: Allakos Inc., Avadel Pharmaceuticals plc, Krystal Biotech, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Allakos Inc. (“Allakos” or the “Company”) (NASDAQ: ALLK) in the United States District Court for the Northern District of Calif...

The investment research arm of Barclays (NYSE: BCS ,LSE:BARC) is not worried about drug pricing concerns in the US; instead, it has a positive outlook for the country’s biopharma industry. On Wednesday (February 26), Barclays Capital launched its coverage of the US biopharma space w...

Allakos (NASDAQ: ALLK ) slides 7.3%  after Muddy Waters says it is short on the company, citing an undisclosed Phase 1 trial that "raises troubling concerns." More news on: Allakos Inc., Healthcare stocks news, Stocks on the move, Read more ...

Allakos (NASDAQ: ALLK ): Q4 GAAP EPS of -$0.51. More news on: Allakos Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

REDWOOD CITY, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the Company) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today reported financial results for the fourth quarter and full year ended...

REDWOOD CITY, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced that the Company will present clinical and ...

Allakos (NASDAQ: ALLK ) resumed with Neutral rating and $94 (27% upside) at Goldman Sachs. More news on: Incyte Corporation, National Vision Holdings, Inc., Tandem Diabetes Care, Inc., Healthcare stocks news, Stocks on the move, , Read more ...